

Case Docket No. ABGENIX.057A

Date: June 23, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Zapata, Gerardo

Appl. No.

10/688,198

Filed

October 17, 2003

For

SYSTEM AND METHOD FOR

**CLEAVING ANTIBODIES** 

Examiner

Unassigned

Group Art Unit:

1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

June 23, 2004 (Date)

Erik T. Anderson, Reg. No. 52,559

## TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirteen (13) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Erik T. Anderson Registration No. 52,559 Attorney of Record Customer No. 20,995 (619) 235-8550 Docket No.: ABGENIX.057A Customer No. 20,995

INFORMATION DISCLOSURE STATEMENT

blicant(s)

Zapata, Gerardo

Appl. No.

10/688,198

Filed

JUN 2 5 2004

October 17, 2003

For

SYSTEM AND METHOD FOR

CLEAVING ANTIBODIES

Examiner

Unassigned

Group Art Unit

1644

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing thirteen (13) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/23/04

By:

Erik T. Anderson Registration No. 52,559

Attorney of Record

Customer No. 20,995

(619) 235-8550

				0111	<u> </u>	
	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABGENIX.057A	APPLICATION NO. 10/688,198		
		DISCLOSURE STATEMENT				
	1	YAPPLICANT	APPLICANT Zapata, Gerardo			
P.	<i>5/</i>	L SHEETS IF NECESSARY)	FILING DATE October 17, 2003	GROUP 1644		
٧3						

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,735,210	04/05/88	Goldenberg			
	2	5,101,827	04/07/92	Goldenberg			
	3	5,102,990	04/07/92	Rhodes			
	4	Re. 35,500	05/06/97	Rhodes		,	
	5	5,194,594	03/16/93	Khawli, et al.			
	6	5,648,471	07/15/97	Buttram, et al.			
	7	5,697,902	12/16/97	Goldenberg			
	8	6,066,719	05/23/00	Zapata			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)				
		Cancer Chemotherapy and Biotherapy: Principles and Practice, 2 <sup>nd</sup> Edition, Chabner and Longo eds., Lippincott-Raven Publishers, Philadelphia, pp. 655-689, (1996).			
		Kearney, et al., "A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines", The Journal of Immunology, vol. 123, no. 4, pp. 1548-1550, (October 1979).			
		Urlaub, et al., "Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells", Cell, vol. 33, pp. 405-412, (June 1983).			
		Urlaub, et al., "Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions", Somatic Cell and Molecular Genetics, vol. 12, no. 6, pp. 555-566, (1986).			
	13	Vitetta, et al., "Immunotoxins: magic bullets or misguided missiles?", Immunology Today, vol. 14, no. 6, pp. 252-259, (1993)			

S:\DOCS\ETA\ETA-2165.DOC/cfg/062104

EXAMINER			

DATE CONSIDERED